

Endoscopic Procedures for the Treatment of Gastroesophageal Reflux Disease (GERD)

Date of Origin: 10/2004

Last Review Date: 07/22/2020

Effective Date: 08/01/2020

Dates Reviewed: 09/2005, 09/2006, 09/2007, 09/2008, 07/2010, 07/2011, 06/2012, 04/2013, 03/2014, 06/201802/2015, 03/2016, 01/2018, 06/2018, 07/2019, 07/2020

Developed By: Medical Necessity Criteria Committee

I. Description

Gastroesophageal reflux disease (GERD) occurs as a result of the stomach contents leaking back into the esophagus due to the improper closing of the lower esophageal sphincter (LES). The refluxed acid causes a burning sensation in the esophagus commonly called heartburn. If heartburn occurs more than two times a week, it may be considered GERD. Symptoms include heartburn, acid reflux, morning hoarseness, difficulty swallowing, dry cough and pain in the chest. Recurring GERD can cause severe damage to the esophagus. The mildest form of GERD may be controlled with lifestyle modifications or over-the-counter medications. Proton pump inhibitors (PPIs) are then used for patients who fail initial treatment. Surgery may be considered when these therapies fail. Laparoscopic fundoplication is the standard surgical method for treating GERD; however, newer, less invasive endoscopic methods are becoming more readily available. The following procedures have been investigated for the treatment and management of GERD:

Transoral Incisionless Fundoplication: Transoral Incisionless Fundoplication (TIF) performed with the EsophyX® device is an endoscopic procedure for the treatment of gastroesophageal reflux disease (GERD). The TIF procedure clinical objectives are a) to mechanically repair a defective gastroesophageal valve and b) to reduce small hiatal hernias. The goal of therapy is to control both the symptoms and mucosal damage. Based on the most recent data, the TIF procedure appears to be a valuable treatment alternative for the management of appropriately selected patients with moderate to severe chronic GERD symptoms.

Radiofrequency Energy or Radiofrequency Thermal Ablation: Thermal energy is delivered to the lower esophageal sphincter (LES) using endoscopically placed needles. Thermal lesions are produced. The mechanism of action of the thermal lesions is not known but may be related to ablation of the nerve pathways responsible for sphincter relaxation. An example of this procedure is the Stretta™ System. This system received FDA approval in 2000 for general use in the electrosurgical coagulation of tissue intended for use in the treatment of GERD.

Gastric Plication/Suturing Techniques: In these types of procedures, sutures are placed in the lower esophageal sphincter. Specifically, a needle puncture device attached to the endoscope creates pleats

through a series of sutures passed by a needle through adjoining proximal fundic folds at the gastroesophageal junction. The sutures are designed to strengthen and lengthen the sphincter in order to decrease reflux. Examples of suture plication gastroplasty devices are the EndoCinch™, Bard Endoscopic Suturing System (BESS), the Full Thickness Plicator™, and the Syntheon ARD Plicator.

Polymer Injection/Implantation Techniques: These types of procedures are known as bulking techniques. The goal is to provide bulking support to the sphincter. Bulking procedures include: endoscopic submucosal implantation of polymethylmethacrylate (PMMA) beads into the lower esophageal folds and implantation of expandable hydrogel prostheses at the gastroesophageal junction. Gatekeeper™ Reflux Repair System is an example of expandable hydrogel prosthesis.

Per-Oral Endoscopic Myotomy (POEM): *Refer to Moda Health Medical Necessity Criteria for Surgical Treatment of Achalasia*

The LINX® Reflux Management System: The laparoscopic placement of magnetic esophageal rings are considered investigational. There is insufficient evidence of randomized-controlled studies that demonstrate the long-term safety and effectiveness of laparoscopically implanted magnetic esophageal rings.

Note: Endoscopic liquid polymer implantation (Boston Scientific Corporation) also known as Enteryx was recalled September 23, 2005 and is no longer available on the market.

II. Criteria: CWQI HCS-0028A

- A. Moda Health considers **transoral incisionless fundoplication (TIF)** medically necessary when **ALL** of the following criteria are met:
- a. 18 years of age or older
 - b. Confirmed diagnosis of esophageal reflux by endoscopy, ambulatory pH, or barium swallow testing.
 - c. History of GERD symptoms for one year occurring 2 to 3 times per week.
 - d. GERD patients with body mass index (BMI) ≤ 35 .
 - e. History of daily proton pump inhibitor's (PPI's) for greater than 6 months
 - f. Absence of **ALL** of the following conditions;
 - i. Hiatal hernia (unless hiatal hernia is 2 cm or less)
 - ii. Esophagitis LA (Los Angeles classification system) grade C or D. (**See Classification below*)
 - iii. Barrett's esophagus
 - iv. Achalasia
 - v. Esophageal ulcer
 - vi. Esophageal motility disorder
 - vii. Altered esophageal anatomy preventing insertion of the device.
 - viii. No previous failed anti-reflux surgery/procedure.

- B. Moda Health considers all other endoscopic procedures for the treatment and management of GERD or other disorders of the esophagus to be experimental and investigational and/or unproven. There is insufficient published scientific evidence to support the long-term effectiveness of these procedures and to show them to be as safe and effective as other options for the treatment of GERD. Endoscopic procedures that are considered experimental and investigational including but not limited to **ALL** of the following:
- a. Angelchik anti-reflux prosthesis
 - b. EndoCinch™ or Bard Endoscopic Suturing System (BESS)
 - c. Apollo OverStitch endoscopic suturing system
 - d. Enteryx (withdrawn from market 2007)
 - e. LINX Reflux Management System (except Medicare) – (*Laparoscopic or open surgical procedure*)
 - f. StomaphyX
 - g. Full-Thickness Plicator™
 - h. Durasphere
 - i. Gatekeeper™ Reflux Repair System
 - j. Plexiglas or polymethylmethacrylate implantation.
 - k. Endoscopic Plicator System
 - l. Stretta™ System
 - m. Syntheon ARD Plicator
 - n. Electrical stimulation of the lower esophageal sphincter (EndoStim)

***The Los Angeles Classification of Oesophagitis:**

- Grade A:** One (or more) mucosal break no longer than 5 mm that does not extend between the tops of two mucosal folds
- Grade B:** One (or more) mucosal break more than 5 mm long that does not extend between the tops of two mucosal folds
- Grade C:** One (or more) mucosal break that is continuous between the tops of two or more mucosal folds, but which involve less than 75% of the circumference
- Grade D:** One (or more) mucosal break which involves at least 75% of the esophageal circumference

III. Information Submitted with the Prior Authorization Request:

1. Provider records of physical exam and symptoms
2. Prior treatments attempted
3. Prior medical history and surgeries/procedures related to GERD

IV. CPT or HCPC codes covered if criteria met:

Codes	Description
43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed
43659	Unlisted laparoscopy procedure, stomach

V. CPT or HCPC codes NOT covered for above listed procedures:

Codes	Description
43201	Esophagoscopy, rigid or flexible; with directed submucosal injection(s), any substance
43236	Upper gastrointestinal endoscopy including esophagus, stomach, and either the duodenum and/or jejunum as appropriate; with directed submucosal injection(s), any substance
43257	Upper gastrointestinal endoscopy including esophagus, stomach, and either the duodenum and/or jejunum as appropriate; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease
43499	Unlisted procedure, esophagus

VI. Annual Review History

Review Date	Revisions	Effective Date
04/2013	Annual Review: Added table with review date, revisions, and effective date.	04/24/2013
04/03/2014	Annual Review: Added Laparoscopically implanted magnetic ring and POEM to investigational procedures	04/03/2014
02/2015	Annual Review: Added description of POEM and statement in criteria regarding other disorders of the esophagus to apply to achalasia tx with POEM	02/25/2015
03/2016	Annual Review – Added ICD-10 codes	03/23/2016
07/2017	Annual Review – removed the LINX from the list of investigational procedures.	07/01/2017
06/2018	Annual Review: added TIF- added LINX back to E&I-removed ICD-10 codes	07/01/2018
07/2019	Annual Review: removed deleted codes, updated list of endoscopic procedures considered E&I	08/01/2019
07/2020	Annual Review: Removed Esophyx device from E/I list. Transoral Incisionless Fundoplication is performed with the Esophyx device as an endoscopic procedure for the treatment of gastroesophageal reflux disease	08/01/2020

VII. References

1. American Gastroenterological Association. Medical position statement on the management of gastroesophageal reflux disease. 2008.
2. Aziz AM, El-Khayat HR, Sadek A, et al. A prospective randomized trial of sham, single-dose Stretta, and double-dose Stretta for the treatment of gastroesophageal reflux disease. Surg Endosc. 2010; 24(4):818-825.

3. Bonavina L, DeMeester T, Fockens P, et al. Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure: One- and 2-year results of a feasibility trial. *Ann Surg.* 2010; 252(5):857-862.
4. Bredenoord AJ. New therapies for gastroesophageal reflux disease. *Minerva Gastroenterol Dietol.* 2010; 56(2):129-138.
5. Cadière GB, Van Sante N, Graves JE, Gawlicka AK, Rajan A. Two-year results of a feasibility study on antireflux transoral incisionless fundoplication using EsophyX. *Surg Endosc.* 2009 May; 23(5):957-64. Epub 2009 Mar 14.
6. Chen, D, Barber, C, McLoughlin, P, Thavaneswaran, P, Jamieson, GG, Maddern, GJ. Systematic review of endoscopic treatments for gastro-oesophageal reflux disease. *Br J Surg.* 2009 Feb; 96(2):128-36. PMID: 19160349
7. Domagk, D, Menzel, J, Seidel, M, et al. Endoluminal gastroplasty (EndoCinch) versus endoscopic polymer implantation (Enteryx) for treatment of gastroesophageal reflux disease: 6-month results of a prospective, randomized trial. *Am J Gastroenterol.* 2006 Mar; 101(3):422-30. PMID: 16542275.
8. FDA preliminary public health notification: recall of Boston Scientific Enteryx® procedure kits and Enteryx® injector single packs for treatment of gastroesophageal reflux disease (GERD). October 14, 2005. Accessed on June 25, 2012 at: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/UCM064523?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=enteryx&utm_content=2
9. Fockens P, Cohen L, Edmundowicz SA, et al. Prospective randomized controlled trial of an injectable esophageal prosthesis versus a sham procedure for endoscopic treatment of gastroesophageal reflux disease. *Surg Endosc.* 2010; 24(6):1387-1397.
10. Haider M, Iqbal A, Filipi CJ. Endoluminal gastroplasty: a new treatment for gastroesophageal reflux disease. *Thorac Surg Clin.* 2005 Aug; 15(3):385-94.
11. Hogan WJ. Clinical trials evaluating endoscopic GERD treatments: is it time for a moratorium on the clinical use of these procedures? *Am J Gastroenterol.* 2006 Mar; 101(3):437-9. Jafri SM, Arora G, Triadafilopoulos G. What is left of the endoscopic antireflux devices? *Curr Opin Gastroenterol.* 2009; 25(4):352-357.
12. Johnson DA. Enteryx implant for gastroesophageal reflux disease. *Curr Treat Options Gastroenterol.* Feb 2005; 8(1):51-57.
13. Montgomery, M, Hakanson, B, Ljungqvist, O, Ahlman, B, Thorell, A. Twelve months' follow-up after treatment with the EndoCinch endoscopic technique for gastro-oesophageal reflux disease: a randomized, placebo-controlled study. *Scand J Gastroenterol.* 2006 Dec; 41(12):1382-9. PMID: 17101568
14. National Institute for Health and Clinical Excellence (NICE). Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease. *Interventional Procedure Guidance 292.* London, UK: NICE; March 2009.
15. National Institute for Health and Clinical Excellence Guidance for care of the digestive system. [cited 08/12/2009]; Assessed on June 25, 2012 at: <http://www.nice.org.uk/guidance/index.jsp?action=byTopic&o=7220>
16. Ozawa S, Yoshida M, Kumai K, et al. New endoscopic treatments for gastroesophageal reflux disease. *Ann Thorac Cardiovasc Surg.* 2005 Jun; 11(3):146-53.
17. Ozawa S, Yoshida M, Kumi K, et al. New endoscopic treatments for gastroesophageal reflux disease. *Ann Thorac Cardiovasc Surg.* 2005. 11(3):146-153.

18. Portale G, Filipi CJ, Peters JH. A current assessment of endoluminal approaches to the treatment of gastroesophageal reflux disease. *Surg Innov.* 2004 Dec; 11(4):225-34.
19. Repici, A, Fumagalli, U, Malesci, A, Barbera, R, Gambaro, C, Rosati, R. Endoluminal fundoplication (ELF) for GERD using EsophyX: a 12-month follow-up in a single-center experience. *J Gastrointest Surg.* 2010 Jan;14(1):1-6. PMID: 19902310.
20. Rothstein RI. Endoscopic therapy of gastroesophageal reflux disease: outcomes of the randomized-controlled trials done to date. *J Clin Gastroenterol.* 2008 May-Jun;42(5):594-602.
21. Schiefke I, Zabel-Langhennig A, Neumann S, et al. Long-term failure of endoscopic gastroplication (EndoCinch). *Gut.* 2005 Jun;54(6):752-8.
22. Schiefke, I, Zabel-Langhennig, A, Neumann, S, Feisthammel, J, Moessner, J, Caca, K. Long term failure of endoscopic gastroplication (EndoCinch). *Gut.* 2005 Jun;54(6):752-8. PMID: 15888777
23. Society of American Gastrointestinal Endoscopic Surgeons (SAGES). SAGES Position Statement on Endolumenal Therapies for Gastrointestinal Diseases. February 2009. Accessed on July 21, 2011 at <http://www.sages.org/publication/id/ENDOL/>
24. Thomson M, Antao B, Hall S, Afzal N, Hurlstone P, Swain CP, et al. Medium-term outcome of endoluminal gastroplication with the EndoCinch device in children. *J Pediatr Gastroenterol Nutr.* 2008 Feb;46(2):172-7.
25. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. Enogastric Solutions EsophyX2 System with SerosaFuse Fastener and Accessories, Model 2.7.5. November 6, 2009. K092400. Accessed June 25, 2012 at: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?db=PMN&id=k092400>
26. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. Bard® Endoscopic Suturing System. March 20, 2000b. K994290. Accessed June 25, 2012 at: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=131815>
27. U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). 510(k) summary. EndoGastric Solutions StomaphyX™ endoluminal fastener and delivery system. March 9, 2007. K062875. Accessed June 25, 2012 at: <http://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm>
28. U.S. Food and Drug Administration (FDA). FDA preliminary public health notification*. Recall of Boston Scientific Enteryx procedure kits and Enteryx injector single packs for treatment of gastroesophageal reflux disease (GERD). Alerts and Notices (Medical Devices). Rockville, MD: FDA; October 14, 2005.
29. von Renteln D, Schiefke I, Fuchs KH, Raczynski S, Philipper M, Breithaupt W, et al. Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease using multiple Plicator implants: 12-month multicenter study results. *Surg Endosc.* 2009 Aug;23(8):1866-75. Epub 2009 May 14.
30. Watson TJ Peters JH. Lower esophageal sphincter injections for the treatment of gastroesophageal reflux disease. *Thorac Surg Clin.* 2005 Aug;15(3):405-15.
31. Yeh RW, Triadafilopoulos G. Endoscopic antireflux therapy: the Stretta procedure. *Thorac Surg Clin.* 2005 Aug;15(3):395-403.
32. Zhi XT, Kavic SM, Park AE. Management of gastroesophageal reflux disease: medications, surgery, or endoscopic therapy? (Current status and trends). *J. Long Term Eff Med Implants.* 2005;15(4):375-88.
33. Physician Advisors

Appendix 1 – Applicable ICD-10 diagnosis codes:

Codes	Description
K21	Gastro-esophageal reflux disease
K21.9	Gastro-esophageal reflux disease without esophagitis

Appendix 1 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD):

Jurisdiction(s): 5, 8	NCD/LCD Document (s):

NCD/LCD Document (s):

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC